Paris, France – October 11, 2022

Enterome, a clinical-stage company developing first-in-class immunomodulatory drugs for cancer and inflammatory diseases based on its unique Mimicry platform, today announces that Pierre Belichard, CEO, will present an overview of the Company and take part in 1-on-1 meetings with institutional investors at the following upcoming investor meetings:

• Solebury / BMO Fall Private Company Showcase which will take place on Thursday, October 13, in New York (US)

– Enterome’s Corporate presentation will take place at 9.20 am EST.

• Jefferies London Healthcare Conference which will take place November 15-17

Enterome’s Chief Business Officer, Anne Dagallier, will take part in 1-on-1 meetings with potential business partners at the Pharma Partnering US Summit which will take place in Boston, MA, on November 17 & 18.

Download the press release (.pdf format)